News | January 25, 2025
Mankind Pharma Q3 FY25 PAT dips 16% to Rs. 385 Cr
Q3 FY25 revenue up 24% to Rs 3,230 crore
Q3 FY25 revenue up 24% to Rs 3,230 crore
PAT after MI is Rs. 41 crore which is 162% increase
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
The Acetaminophen and Ibuprofen tablets will be manufactured at the company’s flagship facility in KRSG, Bengaluru
Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Subscribe To Our Newsletter & Stay Updated
